FDA Reviews PET Drug Production Paperwork
Published Date: 12/29/2025
Notice
Summary
The FDA is asking for public feedback on keeping rules that make sure PET drugs are made safely and correctly. This affects companies that produce these special medical drugs, helping keep patients safe without adding new costs. Comments are open until January 28, 2026, so now’s the time to speak up!
Analyzed Economic Effects
5 provisions identified: 0 benefits, 5 costs, 0 mixed.
Estimated annual recordkeeping burden
FDA estimates the total annual recordkeeping burden for 21 CFR part 212 at 98,833 hours covering 197,665 records. The agency provides breakdowns: Academia/Small Firms & High-Risk Component Manufacture Records: 76 recordkeepers, ~62,644 total records, ~50,862 hours; Corporate Firm Records: 91 recordkeepers, ~131,686 total records, ~45,728 hours; External Control Testing Laboratory Records: 23 recordkeepers, 3,335 total records, ~2,243 hours.
CGMP applies to PET drug makers
If you operate a positron emission tomography (PET) drug production facility — academic, hospital, or commercial — you must follow the FDA's Current Good Manufacturing Practice (CGMP) rules in 21 CFR part 212. The rule covers personnel, quality assurance, facilities and equipment, control of components, production/process controls, laboratory controls, finished product acceptance, packaging/labeling, distribution, complaint handling, and records.
Increase in burden from new small facilities
FDA reports the estimated burden increased by 14,348 hours and 12,851 records compared to prior estimates, and attributes this adjustment to an increase in the estimate of the number of small firms due to new facilities.
One-year record retention requirement
You must keep all records required by 21 CFR part 212 at the PET drug production facility or another reasonably accessible location, ensure they are legible and protected from deterioration or loss, and make them readily available for FDA review and copying. All records and documentation must be retained for at least 1 year from the date of final release (including conditional final release) of a PET drug product.
Sterility-failure disclosure burden
For sterility testing failures under 21 CFR 212.70, FDA estimates 11 respondents will make 3 disclosures each (33 total disclosures) with an average burden of 2.5 hours per disclosure, totaling 83 hours annually.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17215, Evaluation of Therapeutic Equivalence; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Evaluation of Therapeutic Equivalence." This guidance explains FDA's thinking on therapeutic equivalence evaluations and therapeutic equivalence codes (TE codes). FDA's therapeutic equivalence evaluations are listed for multisource prescription drug products approved under the Federal Food, Drug, and Cosmetic Act (FD&C Act) in the active section of the "Approved Drug Products With Therapeutic Equivalence Evaluations" (commonly known as the Orange Book). These therapeutic equivalence evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. This guidance finalizes the draft guidance of the same title issued in July 2022.
2026-17229, Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 066
The Food and Drug Administration (FDA or the Agency) is announcing a publication containing modifications the Agency is making to the list of standards FDA recognizes for use in premarket reviews (FDA Recognized Consensus Standards). This publication, entitled "Modifications to the List of Recognized Standards, Recognition List Number: 066" (Recognition List Number: 066), will assist manufacturers who elect to declare conformity with consensus standards to meet certain requirements for medical devices.
2026-17222, Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry titled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific guidances available to the public on FDA's website. The draft guidances identified in this notice were developed using the process described in that guidance.
Previous / Next Documents
Previous: 2025-23852, Over-the-Counter Monograph Drug User Fee Amendments-OTC Monograph Order Request Fee Rates for Fiscal Year 2026
Starting October 1, 2025, companies that make or request orders for over-the-counter (OTC) drugs will pay new fees to the FDA for fiscal year 2026. These fees help the FDA keep OTC drugs safe and effective. If you’re a manufacturer or submitter, get ready for updated costs that will last through September 30, 2026.
Next: 2025-23862, Determination of Regulatory Review Period for Purposes of Patent Extension; ROMVIMZA
The FDA has set the official review period for the drug ROMVIMZA, which helps the company extend its patent protection. This means the drug maker could get more time to exclusively sell ROMVIMZA, potentially affecting competition and profits. People can challenge the dates or the company’s effort in the review process by early and mid-2026 deadlines.